Drug Trial Radar · NCT06119347
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors
Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,581
Actual
Start
Jan 1, 2020
Primary completion
Jun 30, 2023
Study completion Oct 10, 2023
Sponsor
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 7, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs). The main question it aims to answer is whether the choice between AntiVEGF and ICIs affects the risks of acute kidney injury in cancer patients. Cancer patients receiving AntiVEGF will be compared to those treated with ICIs to see if the AKI incidence is higher in patients receiving ICIs.
Conditions
- AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Interventions
AntiVEGFDrug
anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
ICIsDrug
immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- accumulative incidence of sustained AKITime frame: 12 months after index date
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.